BioCentury
ARTICLE | Company News

Microbiotix partners with AMR Centre to develop bacterial virulence inhibitor

November 3, 2017 7:32 PM UTC

Microbiotix Inc. (Worcester, Mass.) partnered with the Antimicrobial Resistance Centre to develop a bacterial virulence inhibitor candidate targeting drug resistant Gram-negative bacteria including Pseudomonas aeruginosa from Microbiotix's T3SS (type III secretion system) inhibitor project. The AMR Centre is a private-public initiative that provides translational R&D services for development of new antibiotics and diagnostics.

The AMR Centre will provide up to $1.1 million in technical support and project funding. In March, Microbiotix received $1.6 million in an upfront payment and up to $1.6 million in milestones from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) to develop bacterial virulence inhibitors to treat P. aeruginosa infection...